From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Cabamiquine (DDD107498) is a potent and orally active antimalarial agent, inhibits multiple life-cycle stages of the parasite, with an EC50 of 1 nM against P. falciparum 3D7. Cabamiquine inhibits protein synthesis by targeting eEF2/CaMKIII, with an EC50 of 2 nM for WT-PfeEF2 .
Madrasin (DDD00107587) is a splicing inhibitor that prevents formation of both splicing intermediates and products in vitro and interferes with one or more early steps in the pathway of spliceosome assembly. Madrasin also can inhibit pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA in cells .
DDD85646 (IMP-366) is an orally active of trypanosoma brucei N-myristoyltransferase (TbNMT IC50=2 nM; hNMT IC50=4 nM). The enzyme N-myristoyltransferase (NMT) is a potential agent target for human African trypanosomiasis .
DDD-028 is a potent non-opioid, non-cannabinoid analgesic which attenuates neuropathic and inflammatory pain without the possible side effects or abuse potential associated with opioid or cannabinoid activities. DDD-028 can be utilized in analgesic research .
DDD100097 is a potent acyltransferase (TbNMT) inhibitor with an IC50 value of 2 nM. DDD100097 can significantly improve blood-brain barrier permeability. DDD100097 can be used in the study of African trypanosomiasis .
DDD00057570 is a selective M17 leucyl-aminopeptidase (LAP) inhibitor. DDD00057570 inhibits L. major and L. donovani intracellular amastigotes in vitro growth .
DDD489 is a potent and selective Cryptosporidium lysyl-tRNA synthetase (CpKRS) inhibitor with IC50 values of 0.85 uM.DDD489 shows anti-cryptosporidials activity in vitro and in vivo .
DDD2 is a selective and potent VHL-mediated PROTAC NUDT5 degrader. DDD2 induces robust NUDT5 degradation. DDD2 can be used in cancer research, such as lymphocytic leukemia and osteosarcoma . (Structure Note: Pink: NUDT5 inhibitor (HY-176262); Blue: E3 (HY-125845); Black: linker (HY-W001958))
Cabamiquine (DDD107498) succinate is a potent and orally active antimalarial agent, inhibits multiple life-cycle stages of the parasite, with an EC50 of 1 nM against P. falciparum 3D7. Cabamiquine succinate inhibits protein synthesis by targeting eEF2/CaMKIII, with an EC50 of 2 nM for WT-PfeEF2 .
GSK3494245 (DDD01305143) is a potent, orally active, and selective inhibitor of the chymotrypsin-like activity of the parasite proteasome binding in a site sandwiched between the β4 and β5 subunits (IC50=0.16 μM for WT L. donovani proteasomes). GSK3494245 moderately inhibits chymotrypsin-like activity of human proteasome (IC50: purified 26S=13 µM; enriched THP-1 extracts IC50=40µM). GSK3494245 exhibits attractive biological and biosafety properties .
p,p'-DDD (4,4’-DDD) is an organochlorine insecticide, a major metabolite of p,p'-DDT. p,p'-DDD is an agonist at estrogen receptor α(ERα) and ERβ. p,p'-DDD increases DNA damage, apoptosis and necrosis in peripheral blood. p,p'-DDD stimulates cell proliferation in SKBR3 cells. p,p'-DDD activates the AP-1 transcription factor. p,p'-DDD decreases sleep times of barbiturates and steroids in rats .
p,p'-DDD (Standard) is the analytical standard of p,p'-DDD (HY-B1984) . This product is intended for research and analytical applications. p,p'-DDD (4,4’-DDD) is an organochlorine insecticide, a major metabolite of p,p'-DDT. p,p'-DDD is an agonist at estrogen receptor α(ERα) and ERβ. p,p'-DDD increases DNA damage, apoptosis and necrosis in peripheral blood. p,p'-DDD stimulates cell proliferation in SKBR3 cells. p,p'-DDD activates the AP-1 transcription factor. p,p'-DDD decreases sleep times of barbiturates and steroids in rats.
p,p'-DDD-d8 is the deuterium labeled p,p'-DDD[1]. p,p'-DDD (4,4’-DDD) is an organochlorine insecticide, a major metabolite of p,p'-DDT. p,p'-DDD is an agonist at estrogen receptor α(ERα) and ERβ. p,p'-DDD increases DNA damage, apoptosis and necrosis in peripheral blood. p,p'-DDD stimulates cell proliferation in SKBR3 cells. p,p'-DDD activates the AP-1 transcription factor. p,p'-DDD decreases sleep times of barbiturates and steroids in rats .
Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
Mitotane (Standard) is the analytical standard of Mitotane. This product is intended for research and analytical applications. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
p,p'-DDD- 13C12 is 13C labeled p,p'-DDD. p,p'-DDD is a major metabolite of p,p'-DDT. p,p'-DDD occurs in the feces and livers of rats, that are given p,p'-DDT by stomach tube, but not of rats injected intraperitoneally with p,p'-DDT .
Mitotane- 13C12 (2,4′-DDD- 13C12) is 13C labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
Mitotane-d8 is the deuterium labeled Mitotane . Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
Mitotane- 13C6 is the 13C labeled Mitotane . Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
Monomethyl octanoate (Suberic acid monomethyl ester) is an ester product. Monomethyl octanoate is a PROTAC linker that can be used in the synthesis of PROTACs, DDD2 (HY-176261) .
TH10184 is a NUDT5 inhibitor. TH10184 can be conjugated with VH032 (HY-125845) and linker (HY-W001958) to synthesize PROTAC NUDT5 degrader DDD2 (HY-176261) .
TH10184-octanedioic acid is a conjugate of the NUDT5 ligand (HY-176262) and the linker (HY-W001958). TH10184-octanedioic acid can be used for synthesizing PROTAC NUDT5 degrader DDD2 (HY-176261) .
KRT5 Human Pre-designed siRNA Set A contains three designed siRNAs for KRT5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Monomethyl octanoate (Suberic acid monomethyl ester) is an ester product. Monomethyl octanoate is a PROTAC linker that can be used in the synthesis of PROTACs, DDD2 (HY-176261) .
Mitotane- 13C6 is the 13C labeled Mitotane . Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
p,p'-DDD-d8 is the deuterium labeled p,p'-DDD[1]. p,p'-DDD (4,4’-DDD) is an organochlorine insecticide, a major metabolite of p,p'-DDT. p,p'-DDD is an agonist at estrogen receptor α(ERα) and ERβ. p,p'-DDD increases DNA damage, apoptosis and necrosis in peripheral blood. p,p'-DDD stimulates cell proliferation in SKBR3 cells. p,p'-DDD activates the AP-1 transcription factor. p,p'-DDD decreases sleep times of barbiturates and steroids in rats .
p,p'-DDD- 13C12 is 13C labeled p,p'-DDD. p,p'-DDD is a major metabolite of p,p'-DDT. p,p'-DDD occurs in the feces and livers of rats, that are given p,p'-DDT by stomach tube, but not of rats injected intraperitoneally with p,p'-DDT .
Mitotane- 13C12 (2,4′-DDD- 13C12) is 13C labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
Mitotane-d8 is the deuterium labeled Mitotane . Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
Cytokeratin 5 Antibody is an unconjugated, approximately 62 kDa, rabbit-derived, anti-Cytokeratin 5 monoclonal antibody. Cytokeratin 5 Antibody can be used for: WB, IHC-P, IF-Tissue, IF-Cell, FC expriments in human, mouse, rat background without labeling.
CK5 Antibody (YA3786) is a mouse-derived and non-conjugated IgG1 antibody, targeting to CK5. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human, mouse, rat, rabbit, monkey.
Cytokeratin pan Antibody (YA953) is a non-conjugated IgG1 antibody, targeting Cytokeratin pan, with a predicted molecular weight of 62 kDa (observed band size: 62 kDa). Cytokeratin pan Antibody (YA953) can be used for WB experiment in human, mouse, rat background.
Cytokeratin pan Antibody (YA954) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA954), targeting Cytokeratin pan. Cytokeratin pan Antibody (YA954) can be used for IHC-P, ICC/IF experiment in human background.
58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa Cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
IHC-P, WB, ICC/IF, ELISA
Human
Cytokeratin 5/6 Antibody (YA5599) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 5/6. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
IHC-P, ELISA
Human
Cytokeratin 5/6 Antibody (YA5676) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 5/6. It can be applicated for IHC-P, ELISA assays, in the background of human.
KRT5 Human Pre-designed siRNA Set A contains three designed siRNAs for KRT5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
